H.R.3067 - Accelerating the End of Breast Cancer Act of 2011
To provide for the establishment of a Commission to Accelerate the End of Breast Cancer.
Loading Bill Text
Rollover any line of text to comment and/or link to it.
Ms. BASS of California (for herself, Mr. BASS of New Hampshire, Ms. HANABUSA, Mr. SCALISE, Ms. MOORE, Mrs. CAPITO, and Ms. DELAURO) introduced the following bill; which was referred to the Committee on Energy and CommerceCommentsClose CommentsPermalink
SECTION 1. SHORT TITLE.
SEC. 2. TABLE OF CONTENTS.
SEC. 3. FINDINGS.
(2) Worldwide, breast cancer is the most frequently diagnosed cancer in women with 1.3 million cases each year and the leading cause of cancer death with more than 500,000 women dying from the disease in 2010.CommentsClose CommentsPermalink
(4) The National Cancer Institute estimated that breast cancer care in the United States cost $16.5 billion in 2009 and cost the Nation $12.1 billion in lost productivity.CommentsClose CommentsPermalink
SEC. 4. ESTABLISHMENT.
SEC. 5. MISSION; DUTIES.
(1) identify opportunities and ideas within government and the private sector that are key components in achieving the end of breast cancer and which have been overlooked, yet are ripe for collaboration and investment, andCommentsClose CommentsPermalink
(2) identify timely opportunities and scientific discoveries which can be turned into real world strategies to prevent breast cancer and prevent breast cancer metastasis and deaths;CommentsClose CommentsPermalink
(5) identify promising, underdeveloped areas of research that would benefit from a cluster of government, industry, and academia forming innovation communities to rapidly advance knowledge into practice, while creating new opportunities for job creation and advancement;CommentsClose CommentsPermalink
(d) Strategic Vision- Not later than 6 months after the appointment of the initial members of the Commission, the Commission shall submit to the President and the relevant authorizing and appropriations committees of the Congress a description of the Commission’s strategic vision for making progress in achieving the mission described in subsection (a) by January 1, 2020.CommentsClose CommentsPermalink
(e) Annual Reports- The Commission shall submit an annual report to the President, the Congress, and the public describing the Commission’s activities under this section, including its progress in achieving the mission described in subsection (a).CommentsClose CommentsPermalink
SEC. 6. MEMBERSHIP.
(2) VACANCIES- Any member of the Commission appointed to fill a vacancy occurring before the expiration of the term for which the member’s predecessor was appointed shall be appointed only for the remainder of that term. A member may serve after the expiration of that member’s term until a successor has taken office. A vacancy in the Commission shall be filled in the manner in which the original appointment was made.CommentsClose CommentsPermalink
SEC. 7. CHAIRPERSON AND COMMISSIONERS.
(1) DESIGNATION- Of the members of the Commission appointed under section 6(a), the President shall at the time of appointment, designate one to serve as Chairperson of the Commission.CommentsClose CommentsPermalink
(2) QUALIFICATIONS- The Chairperson shall be an individual who, by reason of professional background and experience, is especially qualified to manage areas of study pertaining to ending breast cancer by January 1, 2020.CommentsClose CommentsPermalink
(A) recommending novel proposals, projects, and collaborations based on scientific and technical merit to achieve the mission described in section 5(a) with a focus on strategies for the primary prevention of breast cancer, and methods to prevent breast cancer metastasis;CommentsClose CommentsPermalink
(B) identifying ideas and opportunities to achieve the mission described in section 5(a) that are intellectually compelling, innovative, and imaginative, including such ideas and opportunities not being prioritized for breast cancer relevance within Federal agencies or programs or the private sector;CommentsClose CommentsPermalink
SEC. 8. COORDINATION AND NONDUPLICATION.
To the maximum extent practicable, the Commission shall ensure that the activities of the Commission are coordinated with, and do not duplicate the efforts of, programs and laboratories of other government agencies.CommentsClose CommentsPermalink
SEC. 9. EVALUATION OF THE COMMISSION.
(a) In General- The President shall seek to enter into an agreement with the Institute of Medicine of the National Academy of Sciences under which the Institute, after the Commission has been in operation for 3 years, completes an evaluation of how well the Commission is making progress towards achieving the mission described in section 5(a).CommentsClose CommentsPermalink